NCT00770003View on ClinicalTrials.gov

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

February 28, 2010

Conditions
Allergic Rhinitis
Interventions
DRUG

AZD8848

nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month

DRUG

Placebo

nasal spray solution. Once weekly intranasal administrations for one month.

Trial Locations (2)

Unknown

Research Site, Helsingborg

Research Site, Lund

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY